Galapagos Starts Phase 3 Trial of Filgotinib for Crohn’s Disease

Galapagos Starts Phase 3 Trial of Filgotinib for Crohn’s Disease
Galapagos, a clinical-stage biotech specializing in small molecule medicines, has dosed its first patient in its DIVERSITY (NCT02914561) Phase 3 clinical trial of filgotinib in Crohn’s disease. The trial is currently recruiting participants. The initiation of the trial triggered a $50 million milestone payment from Gilead, the co-developer of filgotinib, a selective inhibitor of the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *